InsightfulValue
← Home

bioMérieux
bioMérieux

Healthcare & biotech / Diagnostic Solutions for Healthcare


Company at a Glance

bioMérieux

📊 Get full analytics about bioMérieux

Sign up for free or log in

📥 Get our free eBook now: "The Checklist Value Investor — A Smarter Way to Pick Stocks"

Price
Live  
Infographic
Infographics
Overview
bioMérieux is a global company based in France that specializes in diagnostic solutions for human diseases and clinical microbiology. The company was founded in 1963 by biochemist Alain Mérieux and is currently led by his son, Alexandre Mérieux.
The company’s main focus is on infectious diseases and helping healthcare professionals make faster and more accurate diagnoses. They offer a wide range of solutions for clinical microbiology, including automated systems for bacterial identification and antibiotic susceptibility testing, and molecular diagnostics for viral and bacterial infections.
In addition to clinical microbiology, bioMérieux also offers solutions for food safety and environmental testing, as well as industrial microbiology for pharmaceutical and cosmetics industries.
Some of their well-known products include VITEK® 2 automated systems, VIDAS® immunoassay systems, and FilmArray® molecular testing platforms. These technologies are used in hospitals, reference laboratories, and food testing facilities around the world.
The company has a strong focus on research and development, with over 20% of their revenue being reinvested into this area. They also have a presence in over 150 countries and employ over 11,000 people worldwide.
Overall, bioMérieux is committed to improving global health by providing innovative and reliable diagnostic solutions to healthcare professionals and patients.
How to explain to a 10 year old kid about the company?
bioMérieux is a company that helps doctors and hospitals figure out what makes people sick. They do this by creating special tests and machines that can detect harmful germs and diseases in our bodies. You can think of them as detectives for health!
The way bioMérieux makes money is by selling these tests and machines to hospitals, labs, and clinics around the world. When a doctor wants to understand why a patient is feeling unwell, they might use one of bioMérieux’s tests. This means that every time a hospital uses their tests, bioMérieux earns money.
bioMérieux is successful for a few reasons. First, they make really good products that help save people’s lives by getting the right diagnosis quickly. They also spend a lot of time and effort making new and better tests, so they’re always staying ahead of the competition. Plus, they work with scientists and researchers to learn about new diseases and how to test for them.
Looking to the future, bioMérieux will likely keep being successful because health care is always important. As new germs and diseases appear, there will always be a need for tests to keep people healthy. Also, more technology and science are being developed every day, which means they can keep improving their tests and help even more people around the world. So, bioMérieux has a bright future ahead!

What is special about the company?
bioMérieux

📈 Want to read more about bioMérieux?

Sign up for free or log in

📚 Your free copy of "The Checklist Value Investor — A Smarter Way to Pick Stocks" is waiting

MS4gUGlvbm VlcmluZyBp biB0aGUgZm llbGQgb2Yg bWljcm9iaW 9sb2d5OiBi aW9Nw6lyaW V1eCBzcGVj aWFsaXplcy BpbiB0aGUg ZmllbGQgb2 YgbWljcm9i aW9sb2d5LC BzcGVjaWZp Y2FsbHkgaW 4gdGhlIGRl dmVsb3BtZW 50IGFuZCBw cm9kdWN0aW 9uIG9mIGRp YWdub3N0aW MgdGVzdHMg Zm9yIGluZm VjdGlvdXMg ZGlzZWFzZX MuIFRoZXkg aGF2ZSBiZW VuIGF0IHRo ZSBmb3JlZn JvbnQgb2Yg dGhpcyBmaW VsZCBmb3Ig bW9yZSB0aG FuIDU1IHll YXJzLCBjb2 5zdGFudGx5 IGlubm92YX RpbmcgYW5k IGFkdmFuY2 luZyB0aGUg dXNlIG9mIG 1pY3JvYmlv bG9neSBpbi BoZWFsdGhj YXJlLjxicj 4yLiBHbG9i YWwgcHJlc2 VuY2U6IFRo ZSBjb21wYW 55IG9wZXJh dGVzIGluIG 92ZXIgMTYw IGNvdW50cm llcywgd2l0 aCBhIHN0cm 9uZyBwcmVz ZW5jZSBpbi BFdXJvcGUs IE5vcnRoIE FtZXJpY2Es IGFuZCBBc2 lhLiBUaGlz IGdsb2JhbC ByZWFjaCBh bGxvd3MgdG hlbSB0byBw cm92aWRlIH RoZWlyIGRp YWdub3N0aW Mgc29sdXRp b25zIHRvIG Egd2lkZSBy YW5nZSBvZi BjdXN0b21l cnMsIGZyb2 0gbGFib3Jh dG9yaWVzIH RvIGhvc3Bp dGFsIHN5c3 RlbXMgYW5k IHB1YmxpYy BoZWFsdGgg b3JnYW5pem F0aW9ucy48 YnI+My4gRG VkaWNhdGlv biB0byBwdW JsaWMgaGVh bHRoOiBiaW 9Nw6lyaWV1 eCBpcyBjb2 1taXR0ZWQg dG8gaW1wcm 92aW5nIHB1 YmxpYyBoZW FsdGggYW5k IHBsYXlzIG EgY3J1Y2lh bCByb2xlIG luIHRoZSBw cmV2ZW50aW 9uLCBkaWFn bm9zaXMsIG FuZCBtb25p dG9yaW5nIG 9mIGluZmVj dGlvdXMgZG lzZWFzZXMs IHdoaWNoIG hhdmUgYSBt YWpvciBpbX BhY3Qgb24g Z2xvYmFsIG hlYWx0aC4g VGhlaXIgaW 5ub3ZhdGl2 ZSBkaWFnbm 9zdGljIHRl Y2hub2xvZ2 llcyBoZWxw IGhlYWx0aG NhcmUgcHJv dmlkZXJzIG 1ha2UgYWNj dXJhdGUgYW 5kIHRpbWVs eSBkaWFnbm 9zZXMsIGxl YWRpbmcgdG 8gYmV0dGVy IHBhdGllbn Qgb3V0Y29t ZXMgYW5kIH RoZSBjb250 cm9sIG9mIG VwaWRlbWlj cy48YnI+NC 4gV2lkZSBy YW5nZSBvZi Bwcm9kdWN0 czogVGhlIG NvbXBhbnkg b2ZmZXJzIG EgY29tcHJl aGVuc2l2ZS ByYW5nZSBv ZiBkaWFnbm 9zdGljIHNv bHV0aW9ucy Bmb3IgdmFy aW91cyBzZW dtZW50cyBv ZiB0aGUgaG VhbHRoY2Fy ZSBpbmR1c3 RyeSwgaW5j bHVkaW5nIG NsaW5pY2Fs IG1pY3JvYm lvbG9neSwg aW1tdW5vYX NzYXlzLCBt b2xlY3VsYX IgYmlvbG9n eSwgYW5kIG luZHVzdHJp YWwgbWljcm 9iaW9sb2d5 LiBUaGlzIG RpdmVyc2Ug cG9ydGZvbG lvIGFsbG93 cyB0aGVtIH RvIGNhdGVy IHRvIGRpZm ZlcmVudCBu ZWVkcyBhbm QgcHJvdmlk ZSBjb21wcm VoZW5zaXZl IHNvbHV0aW 9ucyB0byB0 aGVpciBjdX N0b21lcnMu PGJyPjUuIE ludmVzdG1l bnQgaW4gcm VzZWFyY2gg YW5kIGRldm Vsb3BtZW50 OiBiaW9Nw6 lyaWV1eCBp bnZlc3RzIG Fyb3VuZCAx MCUgb2YgaX RzIGFubnVh bCByZXZlbn VlcyBpbiBy ZXNlYXJjaC BhbmQgZGV2 ZWxvcG1lbn QgdG8gY29u c3RhbnRseS BpbXByb3Zl IGFuZCBleH BhbmQgaXRz IHByb2R1Y3 Qgb2ZmZXJp bmdzLiBUaG lzIGludmVz dG1lbnQgaG FzIGVuYWJs ZWQgdGhlbS B0byBkZXZl bG9wIGN1dH RpbmctZWRn ZSB0ZWNobm 9sb2dpZXMs IHN1Y2ggYX MgYXV0b21h dGVkIG1pY3 JvYmlvbG9n eSBzeXN0ZW 1zIGFuZCBt b2xlY3VsYX ItYmFzZWQg dGVzdHMgZm 9yIGZhc3Rl ciBhbmQgbW 9yZSBhY2N1 cmF0ZSBkaW Fnbm9zaXMu PGJyPjYuIE ZvY3VzIG9u IHN1c3RhaW 5hYmlsaXR5 OiBUaGUgY2 9tcGFueSBp cyBjb21taX R0ZWQgdG8g c3VzdGFpbm FibGUgZGV2 ZWxvcG1lbn QgYW5kIGhh cyBpbXBsZW 1lbnRlZCB2 YXJpb3VzIG luaXRpYXRp dmVzIHRvIH JlZHVjZSBp dHMgZW52aX Jvbm1lbnRh bCBpbXBhY3 QuIFRoaXMg aW5jbHVkZX MgdXNpbmcg cmVzcG9uc2 libGUgc291 cmNpbmcsIG 9wdGltaXpp bmcgcHJvZH VjdCBwYWNr YWdpbmcsIG FuZCBpbXBs ZW1lbnRpbm cgZWNvLWZy aWVuZGx5IG 1hbnVmYWN0 dXJpbmcgcH JvY2Vzc2Vz Ljxicj43Li BDb2xsYWJv cmF0aW9ucy BhbmQgcGFy dG5lcnNoaX BzOiBiaW9N w6lyaWV1eC Bjb2xsYWJv cmF0ZXMgd2 l0aCBvcmdh bml6YXRpb2 5zLCB1bml2 ZXJzaXRpZX MsIGFuZCBy ZXNlYXJjaC BjZW50ZXJz IHRvIHByb2 1vdGUgc2Np ZW50aWZpYy Bwcm9ncmVz cyBhbmQgYW R2YW5jZSBo ZWFsdGhjYX JlIHNvbHV0 aW9ucy4gU2 9tZSBvZiB0 aGVpciBub3 RhYmxlIHBh cnRuZXJzaG lwcyBpbmNs dWRlIGNvbG xhYm9yYXRp b25zIHdpdG ggdGhlIFdv cmxkIEhlYW x0aCBPcmdh bml6YXRpb2 4gKFdITykg YW5kIHRoZS BCaWxsIGFu ZCBNZWxpbm RhIEdhdGVz IEZvdW5kYX Rpb24uPGJy PjguIFN0cm 9uZyBjb3Jw b3JhdGUgY3 VsdHVyZTog VGhlIGNvbX BhbnkgdmFs dWVzIGRpdm Vyc2l0eSwg dGVhbXdvcm ssIGFuZCBp bm5vdmF0aW 9uLCB3aGlj aCBhcmUgcm VmbGVjdGVk IGluIGl0cy Bjb3Jwb3Jh dGUgY3VsdH VyZS4gVGhl eSBzdHJpdm UgdG8gbWFp bnRhaW4gYW 4gaW5jbHVz aXZlIGFuZC Bjb2xsYWJv cmF0aXZlIH dvcmsgZW52 aXJvbm1lbn QgdGhhdCBm b3N0ZXJzIG NyZWF0aXZp dHkgYW5kIG VuY291cmFn ZXMgZW1wbG 95ZWVzIHRv IHJlYWNoIH RoZWlyIGZ1 bGwgcG90ZW 50aWFsLjxi cj45LiBRdW FsaXR5IGFz c3VyYW5jZT ogUXVhbGl0 eSBpcyBhIH RvcCBwcmlv cml0eSBmb3 IgYmlvTcOp cmlldXgsIG FuZCB0aGUg Y29tcGFueS BoYXMgc3Ry aWN0IHF1YW xpdHkgYXNz dXJhbmNlIH Byb2Nlc3Nl cyBpbiBwbG FjZSB0byBl bnN1cmUgdG hlIHJlbGlh YmlsaXR5IG FuZCBhY2N1 cmFjeSBvZi B0aGVpciBw cm9kdWN0cy 4gVGhleSBm b2xsb3cgaW 50ZXJuYXRp b25hbCBzdG FuZGFyZHMg YW5kIHJlZ3 VsYXRpb25z IGZvciBwcm 9kdWN0IGRl dmVsb3BtZW 50IGFuZCBt YW51ZmFjdH VyaW5nIHRv IGd1YXJhbn RlZSB0aGUg aGlnaGVzdC BxdWFsaXR5 IHN0YW5kYX Jkcy48YnI+ MTAuIEh1bW FuaXRhcmlh biBlZmZvcn RzOiBiaW9N w6lyaWV1eC BoYXMgYSBz dHJvbmcgY2 9tbWl0bWVu dCB0byBzb2 NpYWwgcmVz cG9uc2liaW xpdHkgYW5k IGxldmVyYW dlcyBpdHMg ZXhwZXJ0aX NlIGFuZCBy ZXNvdXJjZX MgdG8gaW1w cm92ZSBoZW FsdGhjYXJl IGluIHVuZG Vyc2VydmVk IGNvbW11bm l0aWVzLiBU aGlzIGluY2 x1ZGVzIGlu aXRpYXRpdm VzIHN1Y2gg YXMgZG9uYX RpbmcgZGlh Z25vc3RpYy Bzb2x1dGlv bnMgdG8gcm VnaW9ucyBp bXBhY3RlZC BieSBlcGlk ZW1pY3MgYW 5kIHN1cHBv cnRpbmcgaG VhbHRoIGVk dWNhdGlvbi Bwcm9ncmFt cyBpbiBkZX ZlbG9waW5n IGNvdW50cm llcy4=
What the company's business model?
bioMérieux

📈 Want to read more about bioMérieux?

Sign up for free or log in

🔓 Unlock our free guide: "The Checklist Value Investor — A Smarter Way to Pick Stocks"

YmlvTcOpcm lldXggaXMg YSBtdWx0aW 5hdGlvbmFs IGNvbXBhbn kgdGhhdCBz cGVjaWFsaX plcyBpbiBp biB2aXRyby BkaWFnbm9z dGljcywgcG FydGljdWxh cmx5IGluIH RoZSBmaWVs ZHMgb2YgbW ljcm9iaW9s b2d5LCBpbW 11bm9jaGVt aXN0cnksIG FuZCBtb2xl Y3VsYXIgZG lhZ25vc3Rp Y3MuIFRoZW lyIGJ1c2lu ZXNzIG1vZG VsIHJldm9s dmVzIGFyb3 VuZCBkZXZl bG9waW5nLC BtYW51ZmFj dHVyaW5nLC BhbmQgbWFy a2V0aW5nIG RpYWdub3N0 aWMgc29sdX Rpb25zIGZv ciB0aGUgaG VhbHRoY2Fy ZSBpbmR1c3 RyeS48YnI+ VGhlIGNvbX BhbnkncyBi dXNpbmVzcy Btb2RlbCBp cyBiYXNlZC BvbiB0aHJl ZSBtYWluIH BpbGxhcnM6 PGJyPjEuIE lubm92YXRp dmUgRGlhZ2 5vc3RpYyBT b2x1dGlvbn M6IGJpb03D qXJpZXV4IG ludmVzdHMg aGVhdmlseS BpbiByZXNl YXJjaCBhbm QgZGV2ZWxv cG1lbnQgdG 8gY3JlYXRl IGN1dHRpbm ctZWRnZSBk aWFnbm9zdG ljIHNvbHV0 aW9ucyBmb3 IgYSB3aWRl IHJhbmdlIG 9mIGluZmVj dGlvdXMgZG lzZWFzZXMg YW5kIGNvbm RpdGlvbnMu IFRoZXkgYW ltIHRvIHBy b3ZpZGUgYW NjdXJhdGUg YW5kIHJlbG lhYmxlIHJl c3VsdHMgdG 8gaW1wcm92 ZSBwYXRpZW 50IGNhcmUg YW5kIG9wdG ltaXplIGNs aW5pY2FsIG RlY2lzaW9u LW1ha2luZy 48YnI+Mi4g R2xvYmFsIF ByZXNlbmNl OiBXaXRoIG EgcHJlc2Vu Y2UgaW4gb3 ZlciAxNjAg Y291bnRyaW VzLCBiaW9N w6lyaWV1eC BoYXMgYSBz dHJvbmcgZ2 xvYmFsIGZv b3RwcmludC wgYWxsb3dp bmcgdGhlbS B0byByZWFj aCBhIHdpZG UgcmFuZ2Ug b2YgY3VzdG 9tZXJzLiBU aGV5IGhhdm UgYSBsYXJn ZSBuZXR3b3 JrIG9mIHN1 YnNpZGlhcm llcywgZGlz dHJpYnV0b3 JzLCBhbmQg cGFydG5lcn MsIGVuYWJs aW5nIHRoZW 0gdG8gZGVs aXZlciB0aG VpciBzb2x1 dGlvbnMgdG 8gaGVhbHRo Y2FyZSBwcm 92aWRlcnMg d29ybGR3aW RlLjxicj4z LiBDb2xsYW JvcmF0aXZl IEFwcHJvYW NoOiBiaW9N w6lyaWV1eC B3b3JrcyBj bG9zZWx5IH dpdGggaGVh bHRoY2FyZS Bwcm9mZXNz aW9uYWxzLC ByZXNlYXJj aGVycywgYW 5kIHJlZ3Vs YXRvcnkgYm 9kaWVzIHRv IHVuZGVyc3 RhbmQgdGhl aXIgbmVlZH MgYW5kIGRl dmVsb3Agc2 9sdXRpb25z IHRoYXQgbW VldCB0aGVp ciBzcGVjaW ZpYyByZXF1 aXJlbWVudH MuIFRoaXMg Y29sbGFib3 JhdGl2ZSBh cHByb2FjaC BhbGxvd3Mg dGhlbSB0by BzdGF5IGF0 IHRoZSBmb3 JlZnJvbnQg b2YgZGlhZ2 5vc3RpYyBp bm5vdmF0aW 9uIGFuZCBh ZGFwdCB0by BjaGFuZ2lu ZyBoZWFsdG hjYXJlIGxh bmRzY2FwZX MuPGJyPkFk ZGl0aW9uYW xseSwgdGhl IGNvbXBhbn kgb3BlcmF0 ZXMgb24gYS B0d28tYnVz aW5lc3Mgc2 VnbWVudCBt b2RlbCwgd2 l0aCBhIENs aW5pY2FsIE RpYWdub3N0 aWNzIGRpdm lzaW9uIGFu ZCBhIE1vbG VjdWxhciBE aWFnbm9zdG ljcyBkaXZp c2lvbi4gVG hpcyBhbGxv d3MgdGhlbS B0byBjYXRl ciB0byBib3 RoIHJvdXRp bmUgdGVzdG luZyBuZWVk cyBpbiBjbG luaWNhbCBs YWJvcmF0b3 JpZXMgYW5k IHNwZWNpYW xpemVkIG5l ZWRzIGluIH Jlc2VhcmNo IGFuZCBpbm R1c3RyaWFs IHNldHRpbm dzLjxicj5U aGUgY29tcG FueSBhbHNv IGZvY3VzZX Mgb24gc3Vz dGFpbmFiaW xpdHkgYW5k IGNvcnBvcm F0ZSBzb2Np YWwgcmVzcG 9uc2liaWxp dHksIGludG VncmF0aW5n IHRoZXNlIH ZhbHVlcyBp bnRvIHRoZW lyIG9wZXJh dGlvbnMgYW 5kIGRlY2lz aW9uLW1ha2 luZyBwcm9j ZXNzZXMuIF RoaXMgaW5j bHVkZXMgaW 5pdGlhdGl2 ZXMgc3VjaC BhcyByZWR1 Y2luZyB0aG VpciBlbnZp cm9ubWVudG FsIGltcGFj dCwgZW5zdX JpbmcgaGln aCBldGhpY2 FsIHN0YW5k YXJkcywgYW 5kIHN1cHBv cnRpbmcgY2 9tbXVuaXR5 IGhlYWx0aC Bpbml0aWF0 aXZlcy4gT3 ZlcmFsbCwg YmlvTcOpcm lldXgncyBi dXNpbmVzcy Btb2RlbCBy ZXZvbHZlcy Bhcm91bmQg aW5ub3ZhdG lvbiwgZ2xv YmFsIHJlYW NoLCBjb2xs YWJvcmF0aW 9uLCBhbmQg c29jaWFsIH Jlc3BvbnNp YmlsaXR5IH RvIHByb3Zp ZGUgY3V0dG luZy1lZGdl IGRpYWdub3 N0aWMgc29s dXRpb25zIH RvIGltcHJv dmUgaGVhbH RoY2FyZSBv dXRjb21lcy 4=
Is AI a threat?
AI can pose several potential threats to a company like bioMérieux, which specializes in diagnostics and laboratory products. Here are some considerations regarding substitution, disintermediation, and margin pressure:
1. Substitution: AI technologies can lead to the development of advanced diagnostic tools that may outperform traditional products offered by bioMérieux. For instance, AI-driven algorithms that analyze medical images or genomic data could replace certain lab tests, potentially diminishing the demand for bioMérieux’s current offerings.
2. Disintermediation: AI applications may enable healthcare providers to perform tests and obtain results without relying on third-party diagnostic companies. For example, point-of-care testing devices powered by AI could allow clinicians to make immediate decisions without sending samples to a centralized lab, which could disrupt bioMérieux’s business model.
3. Margin Pressure: As AI becomes more integrated into diagnostics, competition may intensify, leading to lower prices for advanced diagnostic solutions. This could pressure bioMérieux’s profit margins, especially if the company struggles to innovate quickly in response to evolving technologies and market expectations.
To mitigate these threats, bioMérieux may need to invest in AI research and development, enhance their product portfolio, and consider partnerships or acquisitions of AI firms to stay competitive in an evolving landscape.
Sensitivity to interest rates
The sensitivity of bioMérieux’s earnings, cash flow, and valuation to changes in interest rates can be analyzed from several angles:
1. Earnings Sensitivity: bioMérieux’s earnings may be impacted by interest rate changes indirectly. Higher interest rates can lead to increased borrowing costs if the company has variable rate debt, potentially squeezing profit margins. Additionally, higher interest rates can lead to reduced consumer and healthcare spending, impacting the demand for bioMérieux’s diagnostic products.
2. Cash Flow Sensitivity: Cash flow can be quite sensitive to interest rate changes, especially if the company relies heavily on debt financing. In a rising interest rate environment, the cost of financing operations or expansion could increase, leading to lower free cash flow. This effect might be more pronounced if bioMérieux has significant capital expenditures or relies on credit for working capital.
3. Valuation Sensitivity: The valuation of bioMérieux is often assessed using discounted cash flow (DCF) analysis, which is influenced by the discount rate. Higher interest rates generally lead to higher discount rates, which can reduce the present value of future cash flows, resulting in a lower valuation. Additionally, higher rates could cause investors to demand higher returns, impacting the company’s market valuation as investors shift their preferences toward fixed-income securities.
Overall, while bioMérieux might not be directly affected by interest rate changes in its core operations, the broader economic effects and its financial structure make it sensitive to shifts in interest rates.
Interesting facts about the company
bioMérieux

📈 Want to read more about bioMérieux?

Sign up for free or log in

✅ Download "The Checklist Value Investor — A Smarter Way to Pick Stocks" — totally free!

CiAgICAgIC AgICAgIDxk aXYgc3R5bG U9J3dpZHRo OiAxMDAlOy BkaXNwbGF5 OiBmbGV4Oy BqdXN0aWZ5 LWNvbnRlbn Q6IGNlbnRl cjsnPgogIC AgICAgICAg ICAgICAgPG RpdiBzdHls ZT0nCiAgIC AgICAgICAg ICAgICAgIC AgZGlzcGxh eTogZmxleD sKICAgICAg ICAgICAgIC AgICAgICBh bGlnbi1pdG VtczogY2Vu dGVyOwogIC AgICAgICAg ICAgICAgIC AgIGJhY2tn cm91bmQtY2 9sb3I6ICNm MGY0Zjg7Ci AgICAgICAg ICAgICAgIC AgICAgYm9y ZGVyOiAxcH ggc29saWQg I2QxZTNmMD sKICAgICAg ICAgICAgIC AgICAgICBi b3JkZXItcm FkaXVzOiAx MHB4OwogIC AgICAgICAg ICAgICAgIC AgIHBhZGRp bmc6IDEwcH g7CiAgICAg ICAgICAgIC AgICAgICAg bWFyZ2luOi AyMHB4IDA7 CiAgICAgIC AgICAgICAg ICAgICAgZm 9udC1mYW1p bHk6ICJTZW dvZSBVSSIs IFJvYm90by wgc2Fucy1z ZXJpZjsKIC AgICAgICAg ICAgICAgIC AgICBib3gt c2hhZG93Oi AwIDJweCA2 cHggcmdiYS gwLCAwLCAw LCAwLjA1KT sKICAgICAg ICAgICAgIC AgICAgICBt YXgtd2lkdG g6IDkwMHB4 OwogICAgIC AgICAgICAg ICAgICAgIH dpZHRoOiAx MDAlOyc+Cg ogICAgICAg ICAgICAgIC AgICAgIDxp bWcgc3JjPS Jhc3NldHMv bG9nb3MvQT NEek44SjRX WkFrVk8wd0 hUbTkud2Vi cCIgYWx0PS JiaW9Nw6ly aWV1eCIgdG l0bGU9ImJp b03DqXJpZX V4IiAgY2xh c3M9ImltZy 1mbHVpZCIg aGVpZ2h0PT kwIHdpZHRo PTkwIGxvYW Rpbmc9J2xh enknIHN0eW xlPSdib3Jk ZXItcmFkaX VzOiA2cHg7 Jz4KCiAgIC AgICAgICAg ICAgICAgIC AgPGRpdiBz dHlsZT0nZm xleDogMTsg dGV4dC1hbG lnbjogY2Vu dGVyOyBtYX JnaW4tbGVm dDogNXB4Oy c+CiAgICAg ICAgICAgIC AgICAgICAg ICAgIDxwIH N0eWxlPSdm b250LXNpem U6IDI2cHg7 IGNvbG9yOi AjMzMzOyBt YXJnaW4tYm 90dG9tOiAx NXB4Oyc+Ci AgICAgICAg ICAgICAgIC AgICAgICAg ICAgICDwn5 OIIFdhbnQg dG8gcmVhZC Btb3JlIGFi b3V0IGJpb0 3DqXJpZXV4 PwogICAgIC AgICAgICAg ICAgICAgIC AgICA8L3A+ CgogICAgIC AgICAgICAg ICAgICAgIC AgICA8YSBo cmVmPSdpbm RleC5waHA/ cGFnZT1zaW dudXAnIHN0 eWxlPScKIC AgICAgICAg ICAgICAgIC AgICAgICAg ICAgIGJhY2 tncm91bmQt Y29sb3I6IC MwMDdCRkY7 CiAgICAgIC AgICAgICAg ICAgICAgIC AgICAgICBj b2xvcjogI2 ZmZjsKICAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgIHBhZGRp bmc6IDEwcH ggMjBweDsK ICAgICAgIC AgICAgICAg ICAgICAgIC AgICAgIGJv cmRlci1yYW RpdXM6IDVw eDsKICAgIC AgICAgICAg ICAgICAgIC AgICAgICAg IHRleHQtZG Vjb3JhdGlv bjogbm9uZT sKICAgICAg ICAgICAgIC AgICAgICAg ICAgICAgIG ZvbnQtd2Vp Z2h0OiBib2 xkOwogICAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgbWFyZ2lu LXJpZ2h0Oi AxMHB4Owog ICAgICAgIC AgICAgICAg ICAgICAgIC AgICAgdHJh bnNpdGlvbj ogYmFja2dy b3VuZC1jb2 xvciAwLjNz IGVhc2U7Jw ogICAgICAg ICAgICAgIC AgICAgICAg ICAgICAgb2 5tb3VzZW92 ZXI9J3RoaX Muc3R5bGUu YmFja2dyb3 VuZENvbG9y PSIjMDA1Nm IzIicKICAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgIG9ubW91 c2VvdXQ9J3 RoaXMuc3R5 bGUuYmFja2 dyb3VuZENv bG9yPSIjMD A3QkZGIic+ CiAgICAgIC AgICAgICAg ICAgICAgIC AgICAgICBT aWduIHVwIG ZvciBmcmVl CiAgICAgIC AgICAgICAg ICAgICAgIC AgIDwvYT4K CiAgICAgIC AgICAgICAg ICAgICAgIC AgIDxzcGFu IHN0eWxlPS dtYXJnaW46 IDAgOHB4Oy Bjb2xvcjog IzU1NTsnPm 9yPC9zcGFu PgoKICAgIC AgICAgICAg ICAgICAgIC AgICAgPGEg aHJlZj0naW 5kZXgucGhw P3BhZ2U9bG 9naW4nIHN0 eWxlPScKIC AgICAgICAg ICAgICAgIC AgICAgICAg ICAgIGNvbG 9yOiAjMDA3 QkZGOwogIC AgICAgICAg ICAgICAgIC AgICAgICAg ICAgdGV4dC 1kZWNvcmF0 aW9uOiB1bm RlcmxpbmU7 CiAgICAgIC AgICAgICAg ICAgICAgIC AgICAgICBm b250LXdlaW dodDogNTAw Oyc+CiAgIC AgICAgICAg ICAgICAgIC AgICAgICAg ICBsb2cgaW 4KICAgICAg ICAgICAgIC AgICAgICAg ICAgPC9hPg oKCiAgICAg ICAgICAgIC AgICAgICAg ICAgIDxwIH N0eWxlPSdt YXJnaW4tdG 9wOiAxNXB4 OyBmb250LX NpemU6IDEz cHg7IGZvbn Qtd2VpZ2h0 OiBib2xkOy Bjb2xvcjog I2QzMmYyZj snPgogICAg ICAgICAgIC AgICAgICAg ICAgICAgIC Ag8J+TmiBZ b3VyIGZyZW UgY29weSBv ZiA8aT4iVG hlIENoZWNr bGlzdCBWYW x1ZSBJbnZl c3RvciDigJ QgQSBTbWFy dGVyIFdheS B0byBQaWNr IFN0b2Nrcy I8L2k+IGlz IHdhaXRpbm cKICAgICAg ICAgICAgIC AgICAgICAg ICAgPC9wPg oKICAgICAg ICAgICAgIC AgICAgICAg ICAgPCEtLQ ogICAgICAg ICAgICAgIC AgICAgICAg ICA8ZGl2IH N0eWxlPSdt YXJnaW4tdG 9wOiAxMnB4 OyBmb250LX NpemU6IDEz cHg7IGNvbG 9yOiAjNDQ0 Oyc+CiAgIC AgICAgICAg ICAgICAgIC AgICAgICAg ICBTaWduIH VwIG5vdyBh bmQgZ2V0IG 91ciBmcmVl IGVCb29rIA ogICAgICAg ICAgICAgIC AgICAgICAg ICAgICAgPG I+VGhlIENo ZWNrbGlzdC BWYWx1ZSBJ bnZlc3Rvci DigJQgQSBT bWFydGVyIF dheSB0byBQ aWNrIFN0b2 NrczwvYj4K ICAgICAgIC AgICAgICAg ICAgICAgIC AgPC9kaXY+ CiAgICAgIC AgICAgICAg ICAgICAgIC AgIC0tPgog ICAgICAgIC AgICAgICAg ICAgICAgIC A8IS0tCiAg ICAgICAgIC AgICAgICAg ICAgICAgID xkaXYgc3R5 bGU9J21hcm dpbi10b3A6 IDE2cHg7IG ZvbnQtc2l6 ZTogMTRweD sgY29sb3I6 ICM0NDQ7IG ZvbnQtZmFt aWx5OiAtYX BwbGUtc3lz dGVtLCBCbG lua01hY1N5 c3RlbUZvbn QsIFNlZ29l IFVJLCBSb2 JvdG8sIEhl bHZldGljYS BOZXVlLCBz YW5zLXNlcm lmOyBsaW5l LWhlaWdodD ogMS42Oyc+ CiAgICAgIC AgICAgICAg ICAgICAgIC AgICAgICBI YXZlIHlvdS BoZWFyZCBh Ym91dCBvdX Igc2hvcnQg PHN0cm9uZy BzdHlsZT0n Zm9udC13ZW lnaHQ6IDYw MDsnPkRhaW x5IFZpZGVv IE5ld3NsZX R0ZXI8L3N0 cm9uZz4/Ci AgICAgICAg ICAgICAgIC AgICAgICAg ICAgICA8YS BocmVmPSdo dHRwczovL3 d3dy5pbnNp Z2h0ZnVsdm FsdWUuY29t L25ld3NsZX R0ZXIucGhw JyB0YXJnZX Q9J19ibGFu aycgc3R5bG U9J2NvbG9y OiAjMDA3Qk ZGOyB0ZXh0 LWRlY29yYX Rpb246IG5v bmU7IGZvbn Qtd2VpZ2h0 OiA1MDA7IG 1hcmdpbi1s ZWZ0OiA2cH g7Jz4KICAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgICAgICBG aW5kIG91dC Btb3JlCiAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgICA8L2E+ CiAgICAgIC AgICAgICAg ICAgICAgIC AgIDwvZGl2 PgogICAgIC AgICAgICAg ICAgICAgIC AgICAtLT4K ICAgICAgIC AgICAgICAg ICAgICA8L2 Rpdj4KICAg ICAgICAgIC AgICAgIDwv ZGl2PgogIC AgICAgICAg ICA8L2Rpdj 4KICAgICAg ICAgICAgCi AgICAgICAg CiAgICAgIC AgPHNwYW4g Y2xhc3M9J2 JsdXJyZWQt dGV4dCc+Ci AgICAgICAg ICAgIE1TNG dSbTkxYm0g UmxaQ0JwYm lBeCBPVFl6 SUdKNUlFIF p5Wlc1amFD QnogWTJsbG JuUnBjMyBS eklFRnNZV2 x1IElFM0Rx WEpwWlggVj RJR0Z1WkNC USBhV1Z5Y2 1VZ1RjIE9w Y21sbGRYZ3 MgSUdKcGIw M0RxWCBKcF pYVjRJR2x6 IElHRWdiR1 ZoWkcgbHVa eUJuYkc5aS BZV3dnWTI5 dGNHIEZ1ZV NCcGJpQjAg YUdVZ1ptbG xiRyBRZ2Iy WWdhVzRnIG RtbDBjbThn WkcgbGhaMj V2YzNScCBZ M011UEdKeV BqIEl1SUZS b1pTQmogYj Ixd1lXNTU0 byBDWmN5Qn VZVzFsIElH TnZiV1Z6SU cgWnliMjBn ZEdobCBJRz FsY21kcGJt IGNnYjJZZ2 RHaGwgSUhk dmNtUnpJRy BKcGIyeHZa M2tnIFlXNW tJRTNEcVgg SnBaWFY0SU MwZyBkR2hs SUd4aGMzIF FnYm1GdFpT QnYgWmlCMG FHVWdZMiA5 dGNHRnVlZU tBIG1YTWda bTkxYm0gUm xjbk11UEdK eSBQak11SU dKcGIwIDNE cVhKcFpYVj QgNG9DWmN5 Qm1hWCBKem RDQndjbTlr IGRXTjBJSG RoY3kgQmhi aUJoZFhSdi BiV0YwWldR Z2MzIGx6ZE dWdElHWnYg Y2lCcFpHVn VkRyBsbWVX bHVaeUJrIG FXWm1aWEps Ym4gUWdkSG x3WlhNZyBi MllnWW1Gam RHIFZ5YVdF c0lIZG8gYV dOb0lHaGxi SCBCbFpDQj BieUJ5IFpY WnZiSFYwYV cgOXVhWHBs SUhSbyBaU0 JtYVdWc1pD IEJ2WmlCdG FXTnkgYjJK cGIyeHZaMy BrdVBHSnlQ alF1IElFbH VJSFJvWlMg QnNZWFJsSU RFNSBOakJ6 TENCaWFXID lOdzZseWFX VjEgZUNCa1 pYWmxiRyA5 d1pXUWdkR2 hsIElHWnBj bk4wSUcgUn BZV2R1YjNO MCBhV01nZE dWemRDIEJt YjNJZ1pHVj AgWldOMGFX NW5JSCBCbG JtbGphV3hz IGFXNGdjbV Z6YVggTjBZ VzVqWlNCcC BiaUJpWVdO MFpYIEpwWV d3Z2FXNW0g WldOMGFXOX VjeSA0OFlu SStOUzRnIF NXNGdkR2hs SUQgRTVOek J6SUdGdSBa Q0F4T1Rnd2 N5IHdnWW1s dlRjT3AgY2 1sbGRYZ2da WCBod1lXNW taV1FnIGFY UnpJSEJ5Yj IgUjFZM1Fn YkdsdSBaU0 IwYnlCcGJt IE5zZFdSbE lHRjEgZEc5 dFlYUmxaQy BCemVYTjBa VzF6IElHWn ZjaUJ0YVcg TnliMkpwYj J4diBaMmxq WVd3Z1lXID VoYkhsemFY TWcgWVc1a0 lIUmxjMyBS eklHWnZjaU JrIFpYUmxZ M1JwYm0gY2 dkbWx5WVd3 ZyBhVzVtWl dOMGFXIDl1 Y3k0OFluSS sgTmk0Z1ZH OWtZWCBrc0 lHSnBiMDNE IHFYSnBaWF Y0SUcgaGhj eUJoSUhCeS BaWE5sYm1O bElHIGx1SU c5MlpYSWcg TVRVd0lHTn ZkVyA1MGNt bGxjeUJoIG JtUWdaVzF3 YkcgOTVjeU J2ZG1WeSBJ REV5TERBd0 1DIEJ3Wlc5 d2JHVWcgZD I5eWJHUjNh VyBSbExqeG ljajQzIExp QlVhR1VnWT IgOXRjR0Z1 ZWVLQSBtWE 1nYUdWaFpI IEYxWVhKMF pYSnogSUdG eVpTQnNiMi BOaGRHVmtJ R2x1IElFMW hjbU41TFcg emlnSmxGZE c5cCBiR1Vz SUVaeVlXID VqWlN3Z2Qy bDAgYUNCdF lXcHZjaSBC d2NtOWtkV0 4wIGFXOXVJ R1poWTIgbH NhWFJwWlhN ZyBhVzRnUm 5KaGJtIE5s TENCMGFHVW cgVlc1cGRH VmtJRiBOMF lYUmxjeXdn IFNYUmhiSG tzSUUgSnlZ WHBwYkN3Zy BZVzVrSUVO b2FXIDVoTG p4aWNqNDQg TGlCaWFXOU 53NiBseWFX VjFlQ0JwIG N5QnJibTkz YmkgQm1iM0 lnYVhSeiBJ R052YlcxcG RHIDFsYm5R Z2RHOGcgYz NWemRHRnBi bSBGaWFXeH BkSGtnIFlX NWtJSGRoY3 kgQjBhR1Vn Wm1seSBjM1 FnWkdsaFoy IDV2YzNScF l5QmogYjIx d1lXNTVJSC BSdklHbHRj R3hsIGJXVn VkQ0IwYUcg VWdSM0psWl c1TSBhV2Rv ZENCd2NtID luY21GdExD QjMgYUdsam FDQmhhVyAx eklIUnZJSE psIFpIVmpa U0IwYUcgVW daVzUyYVhK diBibTFsYm 5SaGJDIEJw YlhCaFkzUW cgYjJZZ2FY UnpJSCBCeW IyUjFZM1J6 IElHRnVaQ0 J2Y0cgVnlZ WFJwYjI1ei BManhpY2o0 NUxpIEJVYU dVZ1kyOXQg Y0dGdWVTQm 9ZWCBNZ1lT QnpkSEp2IG JtY2dabTlq ZFggTWdiMj RnYVc1dSBi M1poZEdsdm JpIHdnZDJs MGFDQnYgZG 1WeUlERXNN aiBBd0lHUm xaR2xqIFlY UmxaQ0J5Wl ggTmxZWEpq YUdWeSBjeU IzYjNKcmFX IDVuSUdsdU lIUm8gWlds eUlGSW1SQy BCalpXNTBa WEp6IElIZH ZjbXhrZDIg bGtaUzQ4WW 5JKyBNVEF1 SUdKcGIwID NEcVhKcFpY VjQgSUdsek lHRnNjMiA4 Z1kyOXRiV2 wwIGRHVmtJ SFJ2SUggQm 9hV3hoYm5S byBjbTl3ZV NCaGJtIFFn ZDI5eWEzTW cgWTJ4dmMy VnNlUyBCM2 FYUm9JRzl5 IFoyRnVhWH BoZEcgbHZi bk1nYzNWai BhQ0JoY3lC MGFHIFVnUW 1sc2JDQW0g SUUxbGJHbH VaRyBFZ1Iy RjBaWE1nIF JtOTFibVJo ZEcgbHZiaU IwYnlCcCBi WEJ5YjNabE lHIEZqWTJW emN5QjAgYn lCa2FXRm5i bSA5emRHbG pJSFJsIGMz UnBibWNnYV cgNGdaR1Yy Wld4diBjR2 x1WnlCamIz IFZ1ZEhKcF pYTXUgUEdK eVBnPT0KIC AgICAgICA8 L3NwYW4+Ci AgICAgICAg CiAgICAgIC Ag
See Company Q&A
bioMérieux

📊 Get full analytics about bioMérieux

Sign up for free or log in

📚 Your free copy of "The Checklist Value Investor — A Smarter Way to Pick Stocks" is waiting

© 2024 - 2026 InsightfulValue.com. All rights reserved. Newsletter
Legal